

Luigi Bolondi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11635736/publications.pdf>

Version: 2024-02-01

85
papers

25,123
citations

57758

44
h-index

53230

85
g-index

86
all docs

86
docs citations

86
times ranked

23010
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Sorafenib in Advanced Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2008, 359, 378-390. | 27.0 | 12,004 |
| 2 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 54-63. | 27.0 | 1,677 |
| 3 | Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1344-1354. | 10.7 | 809 |
| 4 | Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma. <i>Cancer Research</i> , 2007, 67, 6092-6099. | 0.9 | 782 |
| 5 | Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2016, 65, 727-733. | 3.7 | 768 |
| 6 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. <i>Journal of Hepatology</i> , 2012, 57, 821-829. | 3.7 | 736 |
| 7 | The safety of Sonovue® in abdominal applications: Retrospective analysis of 23188 investigations. <i>Ultrasound in Medicine and Biology</i> , 2006, 32, 1369-1375. | 1.5 | 654 |
| 8 | Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359. | 3.6 | 508 |
| 9 | Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. <i>Hepatology</i> , 1992, 16, 132-137. | 7.3 | 410 |
| 10 | Characterization of small nodules in cirrhosis by assessment of vascularity: The problem of hypovascular hepatocellular carcinoma. <i>Hepatology</i> , 2005, 42, 27-34. | 7.3 | 410 |
| 11 | Percutaneous etharrol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. <i>Cancer</i> , 1992, 69, 925-929. | 4.1 | 401 |
| 12 | MiR-199a-3p Regulates mTOR and c-Met to Influence the Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. <i>Cancer Research</i> , 2010, 70, 5184-5193. | 0.9 | 389 |
| 13 | MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. <i>Cancer Research</i> , 2009, 69, 5761-5767. | 0.9 | 380 |
| 14 | Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. <i>Cancer Treatment Reviews</i> , 2019, 72, 28-36. | 7.7 | 342 |
| 15 | MicroRNA-221 Targets Bmf in Hepatocellular Carcinoma and Correlates with Tumor Multifocality. <i>Clinical Cancer Research</i> , 2009, 15, 5073-5081. | 7.0 | 298 |
| 16 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. <i>Lancet Oncology</i> , The, 2018, 19, 682-693. | 10.7 | 285 |
| 17 | MicroRNA involvement in hepatocellular carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2008, 12, 2189-2204. | 3.6 | 248 |
| 18 | Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study. <i>European Journal of Cancer</i> , 2013, 49, 3412-3419. | 2.8 | 218 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Screening for hepatocellular carcinoma in cirrhosis. <i>Journal of Hepatology</i> , 2003, 39, 1076-1084. | 3.7 | 196 |
| 20 | The Impact of Vascular and Nonvascular Findings on the Noninvasive Diagnosis of Small Hepatocellular Carcinoma Based on the EASL and AASLD Criteria. <i>American Journal of Gastroenterology</i> , 2010, 105, 599-609. | 0.4 | 185 |
| 21 | In hepatocellular carcinoma <i>miR-19d</i> is upregulated by p53 and DNA hypomethylation and targets <i>CDKN1A/p21</i> , <i>PTEN</i> , <i>AKT3</i> and <i>TIMP2</i> . <i>Journal of Pathology</i> , 2012, 227, 275-285. | 4.5 | 180 |
| 22 | Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤2cm) HCC in cirrhosis. <i>European Radiology</i> , 2011, 21, 1233-1242. | 4.5 | 174 |
| 23 | The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. <i>Journal of Hepatology</i> , 2017, 67, 173-183. | 3.7 | 165 |
| 24 | Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2013, 45, 712-723. | 0.9 | 155 |
| 25 | Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. <i>Hepatology</i> , 2012, 56, 1025-1033. | 7.3 | 150 |
| 26 | Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. <i>Lancet Oncology</i> , The, 2017, 18, e101-e112. | 10.7 | 123 |
| 27 | Usefulness of contrast-enhanced perfusional sonography in the assessment of hepatocellular carcinoma hypervascular at spiral computed tomography. <i>Journal of Hepatology</i> , 2004, 41, 421-426. | 3.7 | 122 |
| 28 | Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2008, 48, 848-857. | 3.7 | 113 |
| 29 | Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC. <i>PLoS ONE</i> , 2015, 10, e0141448. | 2.5 | 113 |
| 30 | VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE study. <i>International Journal of Cancer</i> , 2014, 135, 1247-1256. | 5.1 | 109 |
| 31 | Characterization of Focal Liver Lesions with Contrast-Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2010, 36, 531-550. | 1.5 | 102 |
| 32 | Yttrium-90 radioembolization vs sorafenib for intermediate-to locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. <i>Liver International</i> , 2015, 35, 1036-1047. | 3.9 | 94 |
| 33 | Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. <i>Liver Transplantation</i> , 2010, 16, 658-667. | 2.4 | 93 |
| 34 | Hepatocellular carcinoma: Epidemiology and clinical aspects. <i>Molecular Aspects of Medicine</i> , 2008, 29, 130-143. | 6.4 | 92 |
| 35 | Conditional Survival after Hepatic Resection for Hepatocellular Carcinoma in Cirrhotic Patients. <i>Clinical Cancer Research</i> , 2012, 18, 4397-4405. | 7.0 | 87 |
| 36 | Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 15350-15364. | 1.8 | 79 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 240-249. | 3.2 | 70 |
| 38 | The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. <i>Cell Death and Disease</i> , 2018, 9, 4. | 6.3 | 68 |
| 39 | Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. <i>BMC Cancer</i> , 2007, 7, 171. | 2.6 | 64 |
| 40 | Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure. <i>Digestive and Liver Disease</i> , 2015, 47, 518-522. | 0.9 | 63 |
| 41 | Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 391-398. | 1.6 | 60 |
| 42 | Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group. <i>Digestive and Liver Disease</i> , 2014, 46, 549-555. | 0.9 | 57 |
| 43 | The intermediate hepatocellular carcinoma stage: Should treatment be expanded?. <i>Digestive and Liver Disease</i> , 2010, 42, S258-S263. | 0.9 | 51 |
| 44 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. <i>ESMO Open</i> , 2020, 5, e000714. | 4.5 | 51 |
| 45 | Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , 2019, 51, 681-688. | 0.9 | 49 |
| 46 | Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. <i>Molecular Imaging and Biology</i> , 2015, 17, 29-37. | 2.6 | 48 |
| 47 | MiR-30e-3p Influences Tumor Phenotype through <i>MDM2</i> / <i>TP53</i> Axis and Predicts Sorafenib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2020, 80, 1720-1734. | 0.9 | 47 |
| 48 | LncRNAs as novel players in hepatocellular carcinoma recurrence. <i>Oncotarget</i> , 2018, 9, 35085-35099. | 1.8 | 46 |
| 49 | Assessment of Vascular Patterns of Small Liver Mass Lesions: Value and Limitation of The Different Doppler Ultrasound Modalities. <i>American Journal of Gastroenterology</i> , 2000, 95, 3537-3546. | 0.4 | 45 |
| 50 | Over-expression of the <i>miR-483-3p</i> overcomes the <i>miR-145/TP53</i> pro-apoptotic loop in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 31361-31371. | 1.8 | 45 |
| 51 | Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. <i>Journal of Hepatology</i> , 2005, 43, 310-316. | 3.7 | 44 |
| 52 | p53/mdm2 Feedback Loop Sustains miR-221 Expression and Dictates the Response to Anticancer Treatments in Hepatocellular Carcinoma. <i>Molecular Cancer Research</i> , 2014, 12, 203-216. | 3.4 | 43 |
| 53 | Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3 β phosphorylation and p21 down-regulation in hepatocellular carcinoma. <i>Oncotarget</i> , 2013, 4, 1618-1631. | 1.8 | 42 |
| 54 | Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. <i>Oncotarget</i> , 2014, 5, 10607-10620. | 1.8 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 171. | 2.4 | 37 |
| 56 | TACE performed in patients with a single nodule of Hepatocellular Carcinoma. <i>BMC Cancer</i> , 2014, 14, 601. | 2.6 | 36 |
| 57 | Treatment of hepatocellular carcinoma in Child-Pugh B patients. <i>Digestive and Liver Disease</i> , 2013, 45, 852-858. | 0.9 | 32 |
| 58 | State of the art: hepatocellular carcinoma. <i>Future Oncology</i> , 2014, 10, 1-6. | 2.4 | 31 |
| 59 | Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma. <i>European Journal of Medicinal Chemistry</i> , 2012, 48, 391-401. | 5.5 | 29 |
| 60 | TP53/MicroRNA Interplay in Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2029. | 4.1 | 26 |
| 61 | From liver cirrhosis to HCC. <i>Internal and Emergency Medicine</i> , 2011, 6, 93-98. | 2.0 | 25 |
| 62 | Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 39609-39626. | 1.8 | 25 |
| 63 | MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma. <i>Acta Histochemica</i> , 2018, 120, 95-102. | 1.8 | 22 |
| 64 | Diagnostic and prognostic value of dna ploidy and cell nuclearity in ultrasound-guided liver biopsies. <i>Cancer</i> , 1994, 74, 1713-1719. | 4.1 | 20 |
| 65 | Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1319-1326. | 2.3 | 20 |
| 66 | In hepatocellular carcinoma AgNOR protein expression correlates with tumour mass doubling time. <i>Journal of Hepatology</i> , 1996, 24, 60-65. | 3.7 | 19 |
| 67 | Recent advances in the diagnosis of hepatocellular carcinoma. <i>Hepatology Research</i> , 2007, 37, S178-92. | 3.4 | 18 |
| 68 | Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials. <i>Liver Cancer</i> , 2017, 6, 337-348. | 7.7 | 18 |
| 69 | Refining sorafenib therapy: lessons from clinical practice. <i>Future Oncology</i> , 2015, 11, 449-465. | 2.4 | 17 |
| 70 | Radiologic criteria of response to systemic treatments for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2017, 4, 129-137. | 4.2 | 16 |
| 71 | Liver metastases from rectal carcinoma: Disease progression during chemotherapy despite loss of arterial-phase hypervascularity on real-time contrast-enhanced harmonic sonography at low acoustic energy. <i>Journal of Clinical Ultrasound</i> , 2003, 31, 387-391. | 0.8 | 15 |
| 72 | Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 119-136. | 4.2 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2397-2407. | 2.3 | 13 |
| 74 | From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma. <i>Histopathology</i> , 2018, 72, 414-422. | 2.9 | 13 |
| 75 | Cost analysis of recall strategies for non-invasive diagnosis of small hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2010, 42, 729-734. | 0.9 | 12 |
| 76 | Durable Complete Response of Hepatocellular Carcinoma after Metronomic Capecitabine. <i>Tumori</i> , 2010, 96, 1028-1030. | 1.1 | 11 |
| 77 | Contrast-enhanced ultrasonography to diagnose complicated acute cholecystitis. <i>Internal and Emergency Medicine</i> , 2016, 11, 19-30. | 2.0 | 11 |
| 78 | Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. <i>Scientific Reports</i> , 2017, 7, 44685. | 3.3 | 11 |
| 79 | A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2011, 43, 1015-1021. | 0.9 | 10 |
| 80 | Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification. <i>Scientific Reports</i> , 2019, 9, 14749. | 3.3 | 9 |
| 81 | Enzymatic cytochemistry, DNA ploidy and AgNOR quantitation in hepatocellular nodules of uncertain malignant potential in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1996, 41, 800-808. | 2.3 | 8 |
| 82 | Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma. <i>BMC Cancer</i> , 2014, 14, 403. | 2.6 | 7 |
| 83 | Contrast-enhanced ultrasound in liver cancer. <i>Hepatic Oncology</i> , 2015, 2, 51-62. | 4.2 | 6 |
| 84 | DAAs for HCV and risk of hepatocellular carcinoma: current standpoint. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 736-738. | 8.1 | 6 |
| 85 | MEDICAL TREATMENT OF HEPATOCELLULAR CARCINOMA. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009021. | 1.3 | 3 |